# Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma

> **NCT01545817** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 74 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Pazopanib followed by everolimus

## Key facts

- **NCT ID:** NCT01545817
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04-19
- **Primary completion:** 2016-11-18
- **Final completion:** 2016-11-18
- **Target enrollment:** 74 (ACTUAL)
- **Why stopped:** As the therapeutic landscape in renal cell carcinoma is changing, it has become apparent that information gained so far by CATChEz study is sufficient.
- **Last updated:** 2019-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01545817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01545817, "Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01545817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*